UttamKeshavRaoMDMBA

Hematology/Oncology

Transplant/cellular therapy, malignant hematology

Dr. Rao is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
901 W Ben White Boulevard Frontage Rd
777 Preston Research Building
Austin, TX 78704

Vanderbilt University Medical CenterHematopoietic Cell Transplantation, 2021 - 2022
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2018 - 2021
University of Alabama Medical CenterResidency, Internal Medicine, 2015 - 2018
Tulane University School of MedicineClass of 2015

PubMed

24 citations
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
Reid W. Merryman, Robert A. Redd, Taiga Nishihori, Julio C. Chavez, Yago Nieto
Blood Advances. 2021-03-23
48 citations
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
Reid W. Merryman, Luca Castagna, Laura Giordano, Vincent T. Ho, Paolo Corradini
Leukemia. 2021-03-03
20 citations
Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
Balabhadrapatruni V. S. K. Chakravarthi, Darshan S. Chandrashekar, Sai Akshaya Hodigere Balasubramanya, Alyncia D. Robinson, Shannon Carskadon
The Prostate. 2018-12-01

Abstracts/Posters

Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Uttam Rao, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Uttam Rao, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019